PhaseBio Pharmaceuticals Gross Profit

Gross Profit of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Profit growth rates and interactive chart. Gross profit is a company's net sales revenue minus its cost of goods sold (or cost of revenue). In other words, it is the sales revenue a company retains after incurring the direct costs associated with producing the goods it sells, and the services it provides.

Highlights and Quick Summary

  • Gross Profit for the quarter ending September 29, 2021 was $335 Thousand (a -96.76% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Profit decreased by -197.95%
  • Annual Gross Profit for 2020 was $320 Thousand (a -86.45% decrease from previous year)
  • Annual Gross Profit for 2019 was $2.36 Million (a -2348.57% decrease from previous year)
  • Annual Gross Profit for 2018 was $-105 Thousand (a 9.38% increase from previous year)
  • Twelve month Gross Profit ending September 29, 2021 was $9.86 Million (a 4.12% increase compared to previous quarter)
  • Twelve month trailing Gross Profit decreased by -7455.97% year-over-year
Trailing Gross Profit for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$9.86 Million $9.47 Million $-928 Thousand $-134 Thousand
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Profit of PhaseBio Pharmaceuticals

Most recent Gross Profitof PHAS including historical data for past 10 years.

Interactive Chart of Gross Profit of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Gross Profit for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.34 $10.34 $-0.47
2020 $-0.34 $-0.06 $-0.06 $0.32 $0.32
2019 $0.76 $0.24 $0.7 $0.65 $2.36
2018 $0.26 $0.41 $-0.11
2017 $-0.1
2016 $-0.09

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.